Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 15 studies | 24% ± 6% | |
intestine | 11 studies | 28% ± 9% | |
lung | 10 studies | 31% ± 11% | |
kidney | 6 studies | 27% ± 8% | |
uterus | 5 studies | 27% ± 2% | |
pancreas | 4 studies | 24% ± 6% | |
liver | 4 studies | 37% ± 14% | |
lymph node | 4 studies | 29% ± 8% | |
ovary | 3 studies | 29% ± 10% | |
adrenal gland | 3 studies | 29% ± 2% | |
eye | 3 studies | 19% ± 4% | |
placenta | 3 studies | 22% ± 7% | |
breast | 3 studies | 20% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 11801.71 | 258 / 258 | 98% | 161.21 | 225 / 230 |
prostate | 97% | 12436.44 | 237 / 245 | 99% | 186.86 | 499 / 502 |
lung | 99% | 7994.52 | 573 / 578 | 97% | 85.93 | 1117 / 1155 |
bladder | 100% | 16548.19 | 21 / 21 | 79% | 54.67 | 400 / 504 |
uterus | 96% | 14619.90 | 163 / 170 | 81% | 93.08 | 374 / 459 |
esophagus | 84% | 18773.84 | 1209 / 1445 | 85% | 67.26 | 156 / 183 |
pancreas | 71% | 10176.12 | 233 / 328 | 98% | 107.26 | 174 / 178 |
intestine | 92% | 13210.54 | 892 / 966 | 72% | 37.15 | 377 / 527 |
stomach | 80% | 5652.73 | 288 / 359 | 76% | 43.53 | 216 / 286 |
breast | 74% | 5450.04 | 341 / 459 | 78% | 54.67 | 874 / 1118 |
kidney | 65% | 2717.62 | 58 / 89 | 80% | 48.34 | 723 / 901 |
brain | 42% | 1952.90 | 1103 / 2642 | 99% | 73.00 | 696 / 705 |
ovary | 92% | 7795.70 | 166 / 180 | 45% | 20.00 | 195 / 430 |
skin | 39% | 1168.03 | 706 / 1809 | 73% | 58.31 | 343 / 472 |
spleen | 100% | 12493.17 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 35.99 | 1 / 1 |
blood vessel | 89% | 6599.80 | 1186 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 86% | 61.73 | 25 / 29 |
peripheral blood | 81% | 18038.85 | 756 / 929 | 0% | 0 | 0 / 0 |
thymus | 28% | 948.14 | 182 / 653 | 51% | 21.35 | 310 / 605 |
tonsil | 0% | 0 | 0 / 0 | 71% | 32.83 | 32 / 45 |
adipose | 64% | 3803.71 | 775 / 1204 | 0% | 0 | 0 / 0 |
liver | 16% | 500.38 | 36 / 226 | 44% | 32.86 | 180 / 406 |
heart | 43% | 1781.93 | 369 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 36% | 19.42 | 29 / 80 |
muscle | 2% | 53.24 | 14 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0050873 | Biological process | brown fat cell differentiation |
GO_0007283 | Biological process | spermatogenesis |
GO_0010976 | Biological process | positive regulation of neuron projection development |
GO_0071877 | Biological process | regulation of adenylate cyclase-inhibiting adrenergic receptor signaling pathway |
GO_0060452 | Biological process | positive regulation of cardiac muscle contraction |
GO_0060087 | Biological process | relaxation of vascular associated smooth muscle |
GO_0055119 | Biological process | relaxation of cardiac muscle |
GO_0045471 | Biological process | response to ethanol |
GO_0045744 | Biological process | negative regulation of G protein-coupled receptor signaling pathway |
GO_0010519 | Biological process | negative regulation of phospholipase activity |
GO_0061052 | Biological process | negative regulation of cell growth involved in cardiac muscle cell development |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0008277 | Biological process | regulation of G protein-coupled receptor signaling pathway |
GO_0043407 | Biological process | negative regulation of MAP kinase activity |
GO_0001975 | Biological process | response to amphetamine |
GO_1900924 | Biological process | negative regulation of glycine import across plasma membrane |
GO_0017148 | Biological process | negative regulation of translation |
GO_0010614 | Biological process | negative regulation of cardiac muscle hypertrophy |
GO_0060135 | Biological process | maternal process involved in female pregnancy |
GO_0005730 | Cellular component | nucleolus |
GO_0005886 | Cellular component | plasma membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0009898 | Cellular component | cytoplasmic side of plasma membrane |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0048487 | Molecular function | beta-tubulin binding |
GO_0001965 | Molecular function | G-protein alpha-subunit binding |
GO_0005096 | Molecular function | GTPase activator activity |
GO_0005516 | Molecular function | calmodulin binding |
GO_0010855 | Molecular function | adenylate cyclase inhibitor activity |
GO_0005515 | Molecular function | protein binding |
GO_0003924 | Molecular function | GTPase activity |
Gene name | RGS2 |
Protein name | RGS2 protein Regulator of G-protein signaling 2 (RGS2) (Cell growth-inhibiting gene 31 protein) (G0/G1 switch regulatory protein 8) |
Synonyms | G0S8 GIG31 |
Description | FUNCTION: Regulates G protein-coupled receptor signaling cascades. Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form . It is involved in the negative regulation of the angiotensin-activated signaling pathway . Plays a role in the regulation of blood pressure in response to signaling via G protein-coupled receptors and GNAQ. Plays a role in regulating the constriction and relaxation of vascular smooth muscle (By similarity). Binds EIF2B5 and blocks its activity, thereby inhibiting the translation of mRNA into protein . . |
Accessions | Q49A86 P41220 ENST00000235382.7 [P41220-1] |